First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)

NCT05832827 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

35

Enrollment

OTHER_GOV

Sponsor class

Conditions

Untreated Advanced or Recurrent Thymic Carcinomas

Interventions

DRUG: MK-3475
DRUG: Lenvatinib
DRUG: Carboplatin
DRUG: Paclitaxel

Sponsor

National Cancer Center, Japan

Collaborators

[object Object]